ChloroquineV1, Istex, Corpus, bibRecord, 000617

Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions

Identifieur interne : 000617 ( Istex/Corpus ); précédent : 000616; suivant : 000618

Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions

Auteurs : C. J. Haagsma ; P. L. C. M. Van Riel ; L. B. A. Van De Putte

Source :

Rheumatology [ 1462-0324 ] ; 1995.

RBID : ISTEX:29FE800555D100EF5CE79670ADB2A347D4B60FE9

Abstract

The use of combinations of second line antirheumatic agents (SLAs) is increasing. There are several reasons for combination therapy, e.g. the unsatisfactory effects of single therapy. Strategies for combining SLAs are to begin with combinations, or to add one or more agents to another. The strategy of adding one agent to another is illustrated by a study of 40 patients having insufficient effect from sulphasalazine (SASP). Patients were randomized between methotrexate (MTX) and the combination of SASP and MTX. The patients were evaluated by a single observer in an open design. The follow-up was 24 weeks. The mean decrease in disease activity score was significantly greater and occurred earlier in the combination group. This favourable response was also present in the other efficacy variables. The incidence of toxicity was equal in both groups. These results support the strategy of adding MTX to SASP when combining these second line antirheumatic drugs.

Url:

https://api.istex.fr/ark:/67375/HXZ-135L5VG2-P/fulltext.pdf

DOI: 10.1093/rheumatology/XXXIV.suppl_4.104

Links to Exploration step

ISTEX:29FE800555D100EF5CE79670ADB2A347D4B60FE9

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions</title>
<author><name sortKey="Haagsma, C J" sort="Haagsma, C J" uniqKey="Haagsma C" first="C. J." last="Haagsma">C. J. Haagsma</name>
<affiliation><mods:affiliation>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>C. J. Haagsma, Department of Rheumatology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Van Riel, P L C M" sort="Van Riel, P L C M" uniqKey="Van Riel P" first="P. L. C. M." last="Van Riel">P. L. C. M. Van Riel</name>
<affiliation><mods:affiliation>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Van De Putte, L B A" sort="Van De Putte, L B A" uniqKey="Van De Putte L" first="L. B. A." last="Van De Putte">L. B. A. Van De Putte</name>
<affiliation><mods:affiliation>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:29FE800555D100EF5CE79670ADB2A347D4B60FE9</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1093/rheumatology/XXXIV.suppl_4.104</idno>
<idno type="url">https://api.istex.fr/ark:/67375/HXZ-135L5VG2-P/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000617</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000617</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions</title>
<author><name sortKey="Haagsma, C J" sort="Haagsma, C J" uniqKey="Haagsma C" first="C. J." last="Haagsma">C. J. Haagsma</name>
<affiliation><mods:affiliation>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>C. J. Haagsma, Department of Rheumatology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Van Riel, P L C M" sort="Van Riel, P L C M" uniqKey="Van Riel P" first="P. L. C. M." last="Van Riel">P. L. C. M. Van Riel</name>
<affiliation><mods:affiliation>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Van De Putte, L B A" sort="Van De Putte, L B A" uniqKey="Van De Putte L" first="L. B. A." last="Van De Putte">L. B. A. Van De Putte</name>
<affiliation><mods:affiliation>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Rheumatology</title>
<idno type="ISSN">1462-0324</idno>
<idno type="eISSN">1462-0332</idno>
<imprint><publisher>Oxford University Press</publisher>
<date when="1995-01">1995</date>
<biblScope unit="vol">XXXIV</biblScope>
<biblScope unit="issue">suppl_4</biblScope>
<biblScope unit="page" from="104">104</biblScope>
<biblScope unit="page" to="108">108</biblScope>
</imprint>
<idno type="ISSN">1462-0324</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1462-0324</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">The use of combinations of second line antirheumatic agents (SLAs) is increasing. There are several reasons for combination therapy, e.g. the unsatisfactory effects of single therapy. Strategies for combining SLAs are to begin with combinations, or to add one or more agents to another. The strategy of adding one agent to another is illustrated by a study of 40 patients having insufficient effect from sulphasalazine (SASP). Patients were randomized between methotrexate (MTX) and the combination of SASP and MTX. The patients were evaluated by a single observer in an open design. The follow-up was 24 weeks. The mean decrease in disease activity score was significantly greater and occurred earlier in the combination group. This favourable response was also present in the other efficacy variables. The incidence of toxicity was equal in both groups. These results support the strategy of adding MTX to SASP when combining these second line antirheumatic drugs.</div>
</front>
</TEI>
<istex><corpusName>oup</corpusName>
<author><json:item><name>C. J. Haagsma</name>
<affiliations><json:string>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</json:string>
<json:string>C. J. Haagsma, Department of Rheumatology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.</json:string>
</affiliations>
</json:item>
<json:item><name>P. L. C. M. van Riel</name>
<affiliations><json:string>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</json:string>
</affiliations>
</json:item>
<json:item><name>L. B. A. van de Putte</name>
<affiliations><json:string>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><value>Combination therapy</value>
</json:item>
<json:item><value>Methotrexate</value>
</json:item>
<json:item><value>Sulphasalazine</value>
</json:item>
<json:item><value>Rheumatoid arthritis</value>
</json:item>
<json:item><value>Clinical trial</value>
</json:item>
</subject>
<arkIstex>ark:/67375/HXZ-135L5VG2-P</arkIstex>
<language><json:string>unknown</json:string>
</language>
<originalGenre><json:string>research-article</json:string>
</originalGenre>
<abstract>The use of combinations of second line antirheumatic agents (SLAs) is increasing. There are several reasons for combination therapy, e.g. the unsatisfactory effects of single therapy. Strategies for combining SLAs are to begin with combinations, or to add one or more agents to another. The strategy of adding one agent to another is illustrated by a study of 40 patients having insufficient effect from sulphasalazine (SASP). Patients were randomized between methotrexate (MTX) and the combination of SASP and MTX. The patients were evaluated by a single observer in an open design. The follow-up was 24 weeks. The mean decrease in disease activity score was significantly greater and occurred earlier in the combination group. This favourable response was also present in the other efficacy variables. The incidence of toxicity was equal in both groups. These results support the strategy of adding MTX to SASP when combining these second line antirheumatic drugs.</abstract>
<qualityIndicators><score>4.752</score>
<pdfWordCount>2952</pdfWordCount>
<pdfCharCount>19004</pdfCharCount>
<pdfVersion>1.2</pdfVersion>
<pdfPageCount>5</pdfPageCount>
<pdfPageSize>628 x 808 pts</pdfPageSize>
<pdfWordsPerPage>590</pdfWordsPerPage>
<pdfText>true</pdfText>
<refBibsNative>false</refBibsNative>
<abstractWordCount>150</abstractWordCount>
<abstractCharCount>966</abstractCharCount>
<keywordCount>5</keywordCount>
</qualityIndicators>
<title>Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions</title>
<genre><json:string>research-article</json:string>
</genre>
<host><title>Rheumatology</title>
<language><json:string>unknown</json:string>
</language>
<issn><json:string>1462-0324</json:string>
</issn>
<eissn><json:string>1462-0332</json:string>
</eissn>
<publisherId><json:string>brheum</json:string>
</publisherId>
<volume>XXXIV</volume>
<issue>suppl-4</issue>
<pages><first>104</first>
<last>108</last>
</pages>
<genre><json:string>journal</json:string>
</genre>
<subject><json:item><value>Combination Therapy</value>
</json:item>
</subject>
</host>
<namedEntities><unitex><date><json:string>1995</json:string>
</date>
<geogName></geogName>
<orgName><json:string>Finland, France and Germany</json:string>
<json:string>Department of Rheumatology, University Hospital Nijmegen</json:string>
<json:string>Society for Rheumatology</json:string>
</orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName><json:string>P.O. Box</json:string>
<json:string>C. J. Haagsma</json:string>
<json:string>Decrease</json:string>
<json:string>The</json:string>
<json:string>Time Overlap</json:string>
<json:string>Time Fio</json:string>
<json:string>Case</json:string>
<json:string>Wilske</json:string>
</persName>
<placeName><json:string>Toxicity</json:string>
<json:string>Netherlands</json:string>
</placeName>
<ref_url></ref_url>
<ref_bibl><json:string>[23]</json:string>
<json:string>[29]</json:string>
<json:string>[22]</json:string>
<json:string>Farr et al. [16]</json:string>
<json:string>[1]</json:string>
<json:string>[21]</json:string>
<json:string>[2, 3]</json:string>
<json:string>Nisar et al.</json:string>
<json:string>[14]</json:string>
<json:string>[7-10]</json:string>
<json:string>Schwarzer et al. [15]</json:string>
<json:string>[4-6]</json:string>
<json:string>[24]</json:string>
<json:string>[7, 11, 12]</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/HXZ-135L5VG2-P</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - rheumatology</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - clinical medicine</json:string>
<json:string>3 - arthritis & rheumatology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Pharmacology (medical)</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Rheumatology</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
<json:string>4 - toxicologie</json:string>
</inist>
</categories>
<publicationDate>1995</publicationDate>
<copyrightDate>1995</copyrightDate>
<doi><json:string>10.1093/rheumatology/XXXIV.suppl_4.104</json:string>
</doi>
<id>29FE800555D100EF5CE79670ADB2A347D4B60FE9</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-135L5VG2-P/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-135L5VG2-P/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-135L5VG2-P/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions</title>
<respStmt><resp>Références bibliographiques récupérées via GROBID</resp>
<name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name>
</respStmt>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Oxford University Press</publisher>
<availability><licence>© 1995 British Society for Rheumatology</licence>
</availability>
<date type="Copyright" when="1995">1995</date>
<date when="1995-01">1995</date>
</publicationStmt>
<notesStmt><note type="content-type" source="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note>
<note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions</title>
<author xml:id="author-0000"><persName><surname>Haagsma</surname>
<forename type="first">C. J.</forename>
</persName>
<affiliation><orgName type="department">Department of Rheumatology</orgName>
<orgName type="institution">University Hospital Nijmegen</orgName>
<address><addrLine>Nijmegen, The Netherlands</addrLine>
</address>
</affiliation>
<affiliation role="corresp">C. J. Haagsma, Department of Rheumatology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.</affiliation>
</author>
<author xml:id="author-0001"><persName><surname>van Riel</surname>
<forename type="first">P. L. C. M.</forename>
</persName>
<affiliation><orgName type="department">Department of Rheumatology</orgName>
<orgName type="institution">University Hospital Nijmegen</orgName>
<address><addrLine>Nijmegen, The Netherlands</addrLine>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><surname>van de Putte</surname>
<forename type="first">L. B. A.</forename>
</persName>
<affiliation><orgName type="department">Department of Rheumatology</orgName>
<orgName type="institution">University Hospital Nijmegen</orgName>
<address><addrLine>Nijmegen, The Netherlands</addrLine>
</address>
</affiliation>
</author>
<idno type="istex">29FE800555D100EF5CE79670ADB2A347D4B60FE9</idno>
<idno type="ark">ark:/67375/HXZ-135L5VG2-P</idno>
<idno type="DOI">10.1093/rheumatology/XXXIV.suppl_4.104</idno>
</analytic>
<monogr><title level="j" type="main">Rheumatology</title>
<idno type="hwp">rheumatology</idno>
<idno type="archive">rheumatology</idno>
<idno type="publisher-id">brheum</idno>
<idno type="pISSN">1462-0324</idno>
<idno type="eISSN">1462-0332</idno>
<imprint><publisher>Oxford University Press</publisher>
<date when="1995-01">1995</date>
<biblScope unit="vol">XXXIV</biblScope>
<biblScope unit="issue">suppl_4</biblScope>
<biblScope unit="page" from="104">104</biblScope>
<biblScope unit="page" to="108">108</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef>
<appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-09"><label>pub2TEI-ISTEX</label>
<desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
                        <ref target="http://www.tei-c.org/">We use TEI</ref>
</desc>
</application>
</appInfo>
</encodingDesc>
<profileDesc><abstract><head>Summary</head>
<p>The use of combinations of second line antirheumatic agents (SLAs) is increasing. There are several reasons for combination therapy, e.g. the unsatisfactory effects of single therapy. Strategies for combining SLAs are to begin with combinations, or to add one or more agents to another. The strategy of adding one agent to another is illustrated by a study of 40 patients having insufficient effect from sulphasalazine (SASP). Patients were randomized between methotrexate (MTX) and the combination of SASP and MTX. The patients were evaluated by a single observer in an open design. The follow-up was 24 weeks. The mean decrease in disease activity score was significantly greater and occurred earlier in the combination group. This favourable response was also present in the other efficacy variables. The incidence of toxicity was equal in both groups. These results support the strategy of adding MTX to SASP when combining these second line antirheumatic drugs.</p>
</abstract>
<textClass ana="subject"><keywords scheme="subject"><term>Combination Therapy</term>
</keywords>
</textClass>
<textClass ana="keyword"><keywords><term>Combination therapy</term>
<term>Methotrexate</term>
<term>Sulphasalazine</term>
<term>Rheumatoid arthritis</term>
<term>Clinical trial</term>
</keywords>
</textClass>
<langUsage><language ident="EN"></language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2019-12-09" who="#istex" xml:id="pub2tei">formatting</change>
<change xml:id="refBibs-istex" who="#ISTEX-API" when="2019-12-12">References added</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-135L5VG2-P/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType>
<istex:document><article article-type="research-article">

<front>

<journal-meta>

<journal-id journal-id-type="hwp">rheumatology</journal-id>

<journal-id journal-id-type="archive">rheumatology</journal-id>

<journal-id journal-id-type="publisher-id">brheum</journal-id>

<journal-title>Rheumatology</journal-title>

<issn pub-type="ppub">1462-0324</issn>

<issn pub-type="epub">1462-0332</issn>

<publisher>

<publisher-name>Oxford University Press</publisher-name>

</publisher>

</journal-meta>

<article-meta>

<article-id pub-id-type="doi">10.1093/rheumatology/XXXIV.suppl_4.104</article-id>

<article-categories>

<subj-group>

<subject>Combination Therapy</subject>

</subj-group>

</article-categories>

<title-group>

<article-title>Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions</article-title>

</title-group>

<contrib-group>

<contrib contrib-type="author">

<name><surname>Haagsma</surname>
<given-names>C. J.</given-names>
</name>
<xref ref-type="corresp" rid="cor1"></xref>

</contrib>

<contrib contrib-type="author">

<name><surname>van Riel</surname>
<given-names>P. L. C. M.</given-names>
</name>

</contrib>

<contrib contrib-type="author">

<name><surname>van de Putte</surname>
<given-names>L. B. A.</given-names>
</name>

</contrib>

<aff><institution>Department of Rheumatology, University Hospital Nijmegen</institution>
 <addr-line>Nijmegen, The Netherlands</addr-line>
</aff>

</contrib-group>

<author-notes>

<corresp id="cor1">C. J. Haagsma, Department of Rheumatology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.</corresp>

</author-notes>

<pub-date pub-type="ppub">

<month>1</month>

<year>1995</year>

</pub-date>

<volume>XXXIV</volume>

<issue>suppl_4</issue>

<fpage>104</fpage>

<lpage>108</lpage>

<copyright-statement>© 1995 British Society for Rheumatology</copyright-statement>

<copyright-year>1995</copyright-year>

<abstract>

<title>Summary</title>

<p>The use of combinations of second line antirheumatic agents (SLAs) is increasing. There are several reasons for combination therapy, e.g. the unsatisfactory effects of single therapy. Strategies for combining SLAs are to begin with combinations, or to add one or more agents to another. The strategy of adding one agent to another is illustrated by a study of 40 patients having insufficient effect from sulphasalazine (SASP). Patients were randomized between methotrexate (MTX) and the combination of SASP and MTX. The patients were evaluated by a single observer in an open design. The follow-up was 24 weeks. The mean decrease in disease activity score was significantly greater and occurred earlier in the combination group. This favourable response was also present in the other efficacy variables. The incidence of toxicity was equal in both groups. These results support the strategy of adding MTX to SASP when combining these second line antirheumatic drugs.</p>
</abstract>

<kwd-group>

<kwd>Combination therapy</kwd>

<kwd>Methotrexate</kwd>

<kwd>Sulphasalazine</kwd>

<kwd>Rheumatoid arthritis</kwd>

<kwd>Clinical trial</kwd>

</kwd-group>

</article-meta>

</front>

</article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo><title>Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA"><title>Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions</title>
</titleInfo>
<name type="personal"><namePart type="given">C. J.</namePart>
<namePart type="family">Haagsma</namePart>
<affiliation>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</affiliation>
<affiliation>C. J. Haagsma, Department of Rheumatology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">P. L. C. M.</namePart>
<namePart type="family">van Riel</namePart>
<affiliation>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">L. B. A.</namePart>
<namePart type="family">van de Putte</namePart>
<affiliation>Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre>
<originInfo><publisher>Oxford University Press</publisher>
<dateIssued encoding="w3cdtf">1995-01</dateIssued>
<copyrightDate encoding="w3cdtf">1995</copyrightDate>
</originInfo>
<abstract>The use of combinations of second line antirheumatic agents (SLAs) is increasing. There are several reasons for combination therapy, e.g. the unsatisfactory effects of single therapy. Strategies for combining SLAs are to begin with combinations, or to add one or more agents to another. The strategy of adding one agent to another is illustrated by a study of 40 patients having insufficient effect from sulphasalazine (SASP). Patients were randomized between methotrexate (MTX) and the combination of SASP and MTX. The patients were evaluated by a single observer in an open design. The follow-up was 24 weeks. The mean decrease in disease activity score was significantly greater and occurred earlier in the combination group. This favourable response was also present in the other efficacy variables. The incidence of toxicity was equal in both groups. These results support the strategy of adding MTX to SASP when combining these second line antirheumatic drugs.</abstract>
<note type="author-notes">C. J. Haagsma, Department of Rheumatology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.</note>
<subject><genre>keywords</genre>
<topic>Combination therapy</topic>
<topic>Methotrexate</topic>
<topic>Sulphasalazine</topic>
<topic>Rheumatoid arthritis</topic>
<topic>Clinical trial</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Rheumatology</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<subject><topic>Combination Therapy</topic>
</subject>
<identifier type="ISSN">1462-0324</identifier>
<identifier type="eISSN">1462-0332</identifier>
<identifier type="PublisherID">brheum</identifier>
<identifier type="PublisherID-hwp">rheumatology</identifier>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>XXXIV</number>
</detail>
<detail type="issue"><number>suppl-4</number>
</detail>
<extent unit="pages"><start>104</start>
<end>108</end>
</extent>
</part>
</relatedItem>
<identifier type="istex">29FE800555D100EF5CE79670ADB2A347D4B60FE9</identifier>
<identifier type="ark">ark:/67375/HXZ-135L5VG2-P</identifier>
<identifier type="DOI">10.1093/rheumatology/XXXIV.suppl_4.104</identifier>
<accessCondition type="use and reproduction" contentType="copyright">© 1995 British Society for Rheumatology</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource>
<recordOrigin>Converted from  (version 1.2.0) to MODS version 3.6.</recordOrigin>
<recordCreationDate encoding="w3cdtf">2019-12-09</recordCreationDate>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-135L5VG2-P/record.json</uri>
</json:item>
</metadata>
<annexes><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-135L5VG2-P/annexes.pdf</uri>
</json:item>
</annexes>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000617 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000617 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:29FE800555D100EF5CE79670ADB2A347D4B60FE9
   |texte=   Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions

Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri